S&P DJI Announces June 2020 Quarterly Rebalance
Filed with ASX · · 10 pages · English
PYC Therapeutics Limited on 6ix
Earlier from PYC Therapeutics
- March 2020 Quarterly Activities and Cash Flow Report
- Successful Efficacy Result on Path to First in Human Studies
- Investor Presentation - February 2020
- CEO Appointment and Establishment of US Office
- Expansion Of Drug Development Pipeline
Later from PYC Therapeutics
- Successful Dose Response & Toxicity Studies in Lead Program
- June 2020 Quarterly Activity Report and Cashflow
- Shareholder Update - Forward View 2020 Milestones
- Executive re-structure across global operations
- Appendix 4E Preliminary Final Report
Follow PYC Therapeutics into a list and get an email when it puts out news.
Follow PYC Therapeutics